文献速递血脂与心血管预防

SARS-CoV-2 mRNA疫苗加强接种与青少年及年轻成人心肌炎风险的北欧队列研究

Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study.
PubMed 文献 · Eur Heart J · 2024-01-01

结果显示,12-39岁男性第三剂接种后28天内急性风险期心肌炎发生率较第二剂后28天以上风险期升高,BNT162b2的IRR为2.08,mRNA-1273的IRR为8.89;但绝对风险低,男性每10万接种者28天内BNT162b2为0.86例、mRNA-1273为1.95例。

要点

  • 12-39岁男性第三剂mRNA疫苗后28天内急性风险期心肌炎发生率高于第二剂后28天以上风险期。
  • BNT162b2第三剂后男性IRR 2.08(95%CI 1.31-3.33),mRNA-1273为8.89(2.26-35.03)。
  • 加强接种后心肌炎绝对风险低,男性每10万接种者28天内BNT162b2为0.86例、mRNA-1273为1.95例。

核心结论

  • 加强接种与青少年及年轻成人心肌炎风险增加相关,但绝对风险低。

主要发现

  • 12-39岁男性第三剂BNT162b2或mRNA-1273后28天急性风险期心肌炎发生率较第二剂后28天以上风险期升高,IRR分别为2.08(95%CI 1.31-3.33)和8.89(2.26-35.03)。
  • 女性仅BNT162b2的IRR可估计,为3.99(95%CI 0.41-38.64)。
  • 男性第三剂BNT162b2和mRNA-1273后28天内绝对风险分别为每10万接种者0.86(95%CI 0.53-1.32)和1.95(0.53-4.99)例心肌炎事件。
  • 女性第三剂BNT162b2后绝对风险为每10万接种者0.15(95%CI 0.04-0.39)例。
  • 疫苗相关病例30天内无死亡。

临床怎么用

  • 临床医生应知晓青少年及年轻成人加强接种后心肌炎风险虽增加但绝对风险低。
  • 对接种后出现心肌炎症状的年轻男性,尤其第三剂BNT162b2或mRNA-1273后28天内,应保持警惕。

局限性

  • 女性mRNA-1273的IRR无法估计,仅BNT162b2可估计且置信区间宽。
  • 研究基于登记数据,可能受诊断编码和监测偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The SARS-CoV-2 mRNA vaccines are associated with an increased risk of myocarditis. This association appears to be strongest in male adolescents and younger males and after the second dose. The aim was to evaluate the risk of myocarditis following SARS-CoV-2 mRNA booster vaccination in 12-to-39-year-olds. METHODS: A multinational cohort study was conducted using nationwide register data in Denmark, Finland, Norway, and Sweden and comprising all 8.9 million individuals residing in each of the four countries. Participants were followed for an inpatient diagnosis of myocarditis. In each of the four countries, Poisson regression was used to estimate adjusted incidence rate ratios (IRRs) of myocarditis comparing vaccination schedules, with associated 95% confidence intervals (CIs). Country-specific results were combined in meta-analyses. RESULTS: A total of 8.9 million residents were followed for 12 271 861 person-years and 1533 cases of myocarditis were identified. In 12-to-39-year-old males, the 28-day acute risk period following the third dose of BNT162b2 or mRNA-1273 was associated with an increased incidence rate of myocarditis compared to the post-acute risk period 28 days or more after the second dose [IRR 2.08 (95% CI 1.31-3.33) and 8.89 (2.26-35.03), respectively]. For females, the corresponding IRR was only estimable for BNT162b2, 3.99 (0.41-38.64). The corresponding absolute risks following the third dose of BNT162b2 and mRNA-1273 in males were 0.86 (95% CI 0.53-1.32) and 1.95 (0.53-4.99) myocarditis events within 28 days per 100 000 individuals vaccinated, respectively. In females, the corresponding absolute risks following the third dose of BNT162b2 were 0.15 (0.04-0.39) events per 100 000 individuals vaccinated. No deaths occurred within 30 days of vaccine-related cases. CONCLUSIONS: The results suggest that a booster dose is associated with increased myocarditis risk in adolescents and young adults. However, the absolute risk of myocarditis following booster vaccination is low.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hviid A, Nieminen TA, Pihlström N, et al. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study. Eur Heart J. 2024. PMID: 38365960. doi:10.1093/eurheartj/ehae056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。